Vyne Therapeutics to Merge With Yarrow Bioscience in All-Stock Deal
Vyne Therapeutics and Yarrow Bioscience plan an all-stock merger to focus on YB-101, a new treatment for Graves’ disease and thyroid eye disease.
/ 2 items
Vyne Therapeutics and Yarrow Bioscience plan an all-stock merger to focus on YB-101, a new treatment for Graves’ disease and thyroid eye disease.
VYNE Therapeutics announced its Phase 2b trial for Repibresib gel in non-segmental vitiligo missed primary and key secondary endpoints, leading to trial termination and a share slump.